3 hours ago

Women in Business Q&A: Susan B. Dillon, Ph.D. Global Therapeutic Area Head, Immunology Janssen https://t.co/ytRfPzbhLV via @HuffPostBlog
5 hours ago

Join us on March 28th in London - our first speaker announced today https://t.co/W7ZuqHR33k #womenonboards #corpgov https://t.co/NAeOVoR0ab
6 hours ago

Aeglea BioTherapeutics appoints Suzanne Bruhn to board https://t.co/1GiFdT9WQQ
6 hours ago

Annalisa Jenkins to join @liftstream and @MedCityHQ as #Chairman of a panel discussion #BoardDiversity #corpgovhttps://t.co/C4t7XYsoRx
6 hours ago

Article in Sunday Times on innovative approach of Akili, backed by @PureTechH and @daphnezohar to treat dementia https://t.co/G62f1kKlqV
1 day ago

2 days ago

3 days ago

Join @liftstream first time in #London on the 28th of March https://t.co/jVaurutfkz for meeting on #boardroomhttps://t.co/S37oi4ptyQ
3 days ago

The Board Meeting on BioPharma Boardroom Diversity https://t.co/xOhXp0y9Iy
3 days ago

A Public Reality for Women in Biotech Boardrooms https://t.co/ua9O8AGxOy
3 days ago

Interesting indeed https://t.co/bPYBJxqRgY
4 days ago

Probably both. Falling in love with the science is not the way to make money investing in “high science” product c… https://t.co/V3lvhgLMF6
4 days ago

Is it driven by my availability of capital or return to 'empire building'? https://t.co/0vKA6jaUgD
4 days ago

This is certainly a limiting factor https://t.co/Y7Wj8Jc4mt
4 days ago

@DonnaYoungDC and their solutions are?
4 days ago

@canaanpartners leader on this issue and have shown how it can bring advantages #biotechboards https://t.co/BQEgTFk3iH
4 days ago

@DonnaYoungDC @IAmBiotech what is it doing?
4 days ago

Retrophin Appoints William Rote Senior Vice President, Research and Development https://t.co/HYRbffU1V0
5 days ago

@gaenorbagley listen to more from Prof. Fernandez at our upcoming conference in London. March 28.
6 days ago

Read all the latest news from Liftstream and the great coverage we've been getting in the media https://t.co/K1BVZuhKIY
6 days ago

7 days ago

Flemming Ornskov, CEO of Shire, on the radar for top-earners! https://t.co/zrd7Fe2VFn
7 days ago

7 days ago

For those of you attending #BIOCEO17 - the next great event in the calendar is on March 28th in London. Be a part o… https://t.co/qpJjg0JQFS
7 days ago

Would really like for you to be involved in our upcoming event @scoutu https://t.co/FmFcXukGB6
7 days ago

MicroVision Announces Changes to its Board of Directors #biotechboards https://t.co/BccEE5xu90
8 days ago

Old, generic drug for rare disease gets new price tag: $89,000 per year https://t.co/leoYz80g0N
8 days ago

Ultragenyx Pharmaceutical Inc. (RARE) Shares Bought by Polar Capital LLP https://t.co/NOtV26LYVN
8 days ago

Cambridge biotech firm Visterra cancels plan for $50 million IPO, cites bad market conditions https://t.co/NH03mbVuay
8 days ago

Activist investor venBio takes issue with Immunomedics' deal with Seattle Genetics - IMMU https://t.co/v4uYGgtH71
9 days ago